Filing Details
- Accession Number:
- 0001104659-10-060074
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-11-26 07:49:15
- Reporting Period:
- 2010-11-26
- Filing Date:
- 2010-11-26
- Accepted Time:
- 2010-11-26 07:49:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1093649 | Idenix Pharmaceuticals Inc | IDIX | Pharmaceutical Preparations (2834) | 450478605 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1030617 | Ag Pharma Novartis | Lichstrasse 35 Basel V8 CH 4002 | No | No | Yes | No | |
1114448 | Ag Novartis | Lichstrasse 35 Basel V8 CH 4002 | No | No | No | Yes |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2010-11-26 | 14,234 | $2.41 | 31,375,635 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2010-11-26 | 822 | $2.64 | 31,376,457 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2010-11-26 | 44 | $2.96 | 31,376,501 | No | 4 | P | Indirect | See footnotes |
Common Stock | Acquisiton | 2010-11-26 | 165 | $3.79 | 31,376,666 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2010-11-26 | 1,332 | $5.11 | 31,377,998 | No | 4 | P | Indirect | See footnote |
Common Stock | Acquisiton | 2010-11-26 | 486 | $5.46 | 31,378,484 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnotes |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Footnotes
- These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities. See attachment.